Alexa Fluor® 594 Anti-CCR9 antibody [EPR26524-59]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CCR9 also known as CD199 is a chemokine receptor known for its role in guiding cell traffic. It is a G-protein-coupled receptor with a mass of approximately 43 kDa. CCR9 is mainly expressed on the surface of thymocytes T lymphocytes and some subsets of dendritic cells. Its presence is especially noted in the small intestine correlated with its role in the migration and function of immune cells in the gut. This receptor is important for the homing of these cells to the intestinal mucosa engaging specifically with its ligand CCL25.

Biological function summary

CCR9 plays a significant role in the immune system particularly in the gut. It is part of chemokine receptor-ligand complexes that are integral to leukocyte trafficking. By interacting with CCL25 CCR9 facilitates the directed movement of immune cells across intestinal tissue impacting the immune surveillance and response within this environment. The receptor's expression pattern also suggests involvement in thymocyte development supporting the immune system's ability to generate a diverse repertoire of T cells.

Pathways

CCR9 is an important component of the chemokine signaling pathway. It is intricately connected to G-protein signaling events triggering downstream effects that drive cell migration and adhesion. This pathway is important for the function and maintenance of mucosal immunity linking CCR9 with CCR7 and its role in guiding T cell migration to specific tissue sites. These pathways collectively support immune functionality and homeostasis underlining CCR9's significance in tissue-specific immunity.

Associated diseases and disorders

CCR9 has associations with inflammatory disorders like Crohn's disease and ulcerative colitis. Inflammatory bowel disease (IBD) is marked by aberrant immune cell movement and function areas where CCR9 is particularly influential. The receptor's interaction with CCL25 is pivotal in these pathological conditions often being a therapeutic target to modulate immune cell trafficking in disease management. Additionally the altered expression of CCR9 may contribute to the progression of specific T-cell leukemias further emphasizing its clinical relevance.